Last edition
News about "FDA Orphan Drug Designation "
Atossa Therapeutics Receives FDA Orphan Drug Designation for Duchenne Therapy
Atossa Therapeutics has received US Food and Drug Administration (FDA) Orphan Drug Designation (ODD) for (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy, further supporting the company’s development programme in rare paediatric neuromuscular diseases.
FDA Orphan Drug Designation | 17/01/2026 | By News Bureau
Ractigen Therapeutics Secures FDA Orphan Drug Designation for RAG-21
RAG-21 is an siRNA therapy specifically designed to target FUS-ALS, one of the most aggressive subtypes of ALS.
FDA Orphan Drug Designation | 20/11/2024 | By Aishwarya | 525
Aisa Pharma Gets FDA Orphan Drug Designation for AISA-021
Aisa is developing AISA-021 for the treatment of Systemic Sclerosis (SSc), a rare disease, which impacts approximately 175,000 Americans and has the highest mortality rate of any autoimmune disease.
FDA Orphan Drug Designation | 10/09/2024 | By Aishwarya | 1107
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy